Participated · Series C · Aug 2024

Caresyntax offers a vendor-neutral precision surgery platform led by CEO Dennis Kogan. Its proprietary software and AI captures and analyzes large volumes of video, audio, images, device, clinical and operational data in and around the operating room to deliver actionable insights, meta-data and real-world evidence. The software and automation platform can be used live during procedures and accessed by users outside the OR via secured dedicated cloud and telehealth links. The platform aims to help surgeons and care teams improve patient outcomes, enable hospital administrators to use resources more efficiently, assist medical device companies to advance products, and support insurers in understanding and controlling risks and enabling value-based contracts. Caresyntax serves over 30,000 surgical professionals across more than 3,000 operating rooms worldwide. The company raised $180M in Series C financing and intends to use the funds to expand operations and its development efforts. Caresyntax provides a digital surgery platform that uses proprietary software and artificial intelligence to analyze large volumes of video, audio, images, device, clinical, and operational data in and around the operating room. The platform delivers actionable insights for care teams and longer-term analytics for stakeholders such as surgeons, and offers virtual, real-time access to outside experts. Caresyntax's software is used in more than 4,000 operating rooms worldwide and supports surgical teams in over two million procedures per year. The company plans to use new funds to continue developing its platform and to advance new data solutions that support value-based care providers. The product emphasis is on improving patient outcomes through immediate and longer-term insights derived from real-world OR data. The company was founded by Dennis Kogan and Björn von Siemens. Caresyntax provides an enterprise-grade digital surgery platform that uses proprietary software and AI to analyze large volumes of video, audio, images, device, clinical, and operational data in and around the operating room. Its platform delivers real-world evidence that care teams can use live during procedures via a telehealth link and post-procedure for benchmarking and improvement. Hospitals can use the platform to manage surgical resources more efficiently, medical device companies can advance products, and insurers can better understand risk. The software is used in more than 4,000 operating rooms worldwide and supports surgical teams in over two million procedures per year. The company announced the acquisition of Syus at the close of 2019, extending its hospital footprint and analytics capabilities. Caresyntax intends to use the new funding to accelerate expansion in key markets, further R&D of its AI analytics, build out its platforms, and grow its employee base. caresyntax provides surgical intelligence and automation solutions that leverage IoT, analytics and AI to integrate data from medical devices, EHRs and other OR sources into a unified platform. Its offerings automate clinical and operational decision support for surgical teams and support outcome contributors across risk-bearing contracts. The company says its technologies are used in more than 7,000 operating rooms worldwide and support over 10 million procedures per year. Recent partnerships with organizations including Mitsubishi’s MC Healthcare, Barco Healthcare, Insel Gruppe AG and University of Wisconsin–Madison aim to expand R&D and global reach. caresyntax plans to use new capital to accelerate domestic and international growth and to further develop and deploy its surgical intelligence and automation technologies. The company works with providers, insurers and device vendors to inform device improvements, support data-driven underwriting and enable value-based contracting. Caresyntax provides a vendor-neutral platform that aggregates structured and unstructured data from operating room devices, electronic health records and other sources into unified dashboards for surgeons and hospital decision makers. Its offerings include PRIME365 OR integration and qvident surgical performance management software, which aim to reduce documentation time, automate workflows, and generate quality data for training and decision support. The company emphasizes granular analysis of surgical variation to recommend fixes that reduce readmissions, improve patient safety and streamline clinical workflows. Caresyntax reports an installed base of more than 6,000 operating rooms, supports over 10 million procedures per year and generates roughly 100 petabytes of high-fidelity data annually. It was launched in 2013 in Germany and established full-time North American operations and a headquarters in Boston in October. The company says it will use the new financing to grow its U.S. business and to develop machine learning and value-added applications for surgical risk management.

Participated · Series A · Oct 2022

Citalid is a SaaS cyber risks management and decision‑support platform that calibrates analysis, simulates pricing, and models the ROI of security investments by cross‑referencing technical, contextual and financial data. Available in SaaS, the tool lets companies assess exposure to cyber risks, prioritize defense and insurance strategies, and simulate associated returns on investment. Founded in 2017 by Maxime Cartan and Alexandre Dieulangard, former ANSSI cyber threat intelligence specialists, Citalid positions itself as a trusted third party between insureds and insurers. In October 2022 the company raised €12.0M in a Series A led by Seventure Partners, with participation from Relyens, Albingia, Fiblac and historical investors Axeleo Capital and BNP Paribas Development. The company plans to use the funding to increase investments in its commercial strike force, strengthen R&D, expand internationally (notably Germany and England), and develop partnerships with distributors and resellers in France and worldwide. Citalid has been awarded two innovation prizes at the Assises de la Sécurité in 2018. Citalid builds a platform that financially evaluates cyber risks for individual clients by analyzing likely threats, defensive maturity, and geopolitical context. Its algorithms model probabilities and financial impacts for the most likely attack scenarios and rely on internationally recognized defensive evaluation criteria (CIS 20, NIST, ISO). The platform models all types of financial loss collaboratively with business teams, from lost productivity to fines and losses in competitiveness or reputation. Citalid’s solution has been adopted by many major French companies, and its R&D team continuously models and integrates new attacks while planning to improve prediction capabilities through AI. The company will use new funding to recruit talent, accelerate growth in France and internationally, and explore new use cases such as cyber insurance. Citalid was founded in 2017 by Maxime Cartan and Alexandre Dieulangard, who previously worked on cyber threat intelligence for France’s national cyber defense authority.

Participated · Series B · Jan 2020

CLEW has developed a real-time AI analytics platform using machine learning and data science to build physiological, predictive models at the individual patient level. The models have been proven successful in the ICU and are being extended to all care settings to guide clinical decision-making. The platform can be deployed at the bedside or to centralized command-and-control facilities to improve outcomes and safety, streamline patient care, and address regulatory and cost pressures. CLEW says its technology can help providers lower the cost of care and remove discharge barriers. The company closed a $20M Series B and reports total capital raised of over $20 million; the financing will be used to scale U.S. operations and commercialize the platform in the TeleICU and critical care markets. Founder and CEO Gal Salomon said the round validates the technology and highlighted strategic value from the partnership with Relyens.